amantadine has been researched along with Day Blindness in 9 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine was reported to decrease serum alanine aminotransferase and HCV RNA levels in chronic hepatitis C patients who had not respond to interferon, but further experience has produced mixed results." | 9.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "Amantadine was reported to decrease serum alanine aminotransferase and HCV RNA levels in chronic hepatitis C patients who had not respond to interferon, but further experience has produced mixed results." | 5.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment." | 1.35 | Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature. ( Ebihara, N; Hattori, N; Iwatake, A; Kubo, S; Murakami, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soin, K | 1 |
| Feinstein, EG | 1 |
| Guo, J | 1 |
| Chrissafidou, A | 1 |
| Musch, E | 1 |
| Kubo, S | 1 |
| Iwatake, A | 1 |
| Ebihara, N | 1 |
| Murakami, A | 1 |
| Hattori, N | 1 |
| Deleu, D | 1 |
| Hanssens, Y | 1 |
| Yagura, M | 1 |
| Harada, H | 1 |
| Pearlman, JT | 2 |
| Kadish, AH | 2 |
| Ramseyer, JC | 2 |
| Fraunfelder, FT | 1 |
| Meyer, SM | 1 |
| Gold, N | 1 |
1 trial available for amantadine and Day Blindness
| Article | Year |
|---|---|
Treatment of chronic hepatitis C patients with amantadine.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Amantadine; Antiviral Agents; Cataract; Cognit | 2001 |
8 other studies available for amantadine and Day Blindness
| Article | Year |
|---|---|
Recent-Onset Bilateral Blurred Vision.
Topics: Amantadine; Antiviral Agents; Corneal Edema; Corneal Pachymetry; Endothelium, Corneal; Female; Human | 2017 |
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
Topics: Adrenal Cortex Hormones; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis | 2009 |
Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
Topics: Amantadine; Antiparkinson Agents; Cornea; Endothelium, Corneal; Humans; Male; Middle Aged; Parkinson | 2008 |
Cerebellar dysfunction in chronic toluene abuse: beneficial response to amantadine hydrochloride.
Topics: Adult; Amantadine; Cerebellar Diseases; Dopamine Agents; Humans; Magnetic Resonance Imaging; Male; S | 2000 |
Vision loss associated with amantadine hydrochloride use.
Topics: Aged; Amantadine; Humans; Male; Tremor; Vision Disorders; Visual Acuity | 1977 |
Vision loss associated with amantadine hydrochloride.
Topics: Aged; Amantadine; Humans; Male; Vision Disorders | 1977 |
Amantadine and corneal deposits.
Topics: Amantadine; Corneal Diseases; Humans; Vision Disorders; Visual Acuity | 1990 |
Visual hallucinations. The unwanted effect of patient compliance.
Topics: Aged; Amantadine; Female; Hallucinations; Humans; Patient Compliance; Vision Disorders | 1985 |